Today, Mylan N.V. (Nasdaq: MYL) and Pfizer Inc. (NYSE: PFE) announced a definitive agreement to combine Mylan with Upjohn, creating a new global pharmaceutical company. Upjohn is Pfizer’s off-patent branded and generic established medicines business.
Together with Cravath, Swaine & Moore LLP, NautaDutilh is serving as legal counsel to Mylan. For NautaDutilh, Leo Groothuis and Paul van der Bijl acted as lead partners.
Pfizer shareholders will own 57% of the combined new company, and Mylan shareholders will own 43%. The combination will be effected through a Reverse Morris Trust, under which Upjohn is expected to be spun off or split off to Pfizer’s shareholders and simultaneously combined with Mylan.
The transaction is anticipated to close in mid-2020, subject to approval by Mylan shareholders and customary closing conditions, including receipt of regulatory approvals.
More information can be found here.